Drug Type Small molecule drug |
Synonyms ASP-3662, ASP3662, SPI-62 |
Target |
Mechanism 11β-HSD1 inhibitors(Corticosteroid 11-beta-dehydrogenase isozyme 1 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC19H16ClF3N4O2 |
InChIKeyCMQOKZCYVZFZLZ-UHFFFAOYSA-N |
CAS Registry1204178-50-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acrocallosal Syndrome | Phase 2 | US | 01 Jul 2023 | |
Acrocallosal Syndrome | Phase 2 | RO | 01 Jul 2023 | |
Acrocallosal Syndrome | Phase 2 | GB | 01 Jul 2023 | |
Acth-Independent Macronodular Adrenal Hyperplasia | Phase 2 | US | 01 Jul 2023 | |
Acth-Independent Macronodular Adrenal Hyperplasia | Phase 2 | RO | 01 Jul 2023 | |
Acth-Independent Macronodular Adrenal Hyperplasia | Phase 2 | GB | 01 Jul 2023 | |
Adrenocortical Adenoma | Phase 2 | US | 01 Jul 2023 | |
Adrenocortical Adenoma | Phase 2 | RO | 01 Jul 2023 | |
Adrenocortical Adenoma | Phase 2 | GB | 01 Jul 2023 | |
Cushing Syndrome | Phase 2 | BG | 01 Sep 2022 |
Phase 2 | 40 | bwzqvxomew(giqkdpybku) = A combination of prednisolone 20 mg with clofutriben showed similar efficacy as prednisolone 10 mg with placebo, based on analysis of participants’ symptoms, physical function, and biomarkers of inflammation. hqwhqpqlye (stqnneqmjg ) View more | Positive | 19 Sep 2024 | |||
SPI-62 + placebo | |||||||
BusinessWire Manual | Phase 2 | - | fvpojlumee(bsyujiugyd) = Prednisolone 10mg combined with clofutriben 6mg demonstrated less efficacy compared to prednisolone 10mg administered with placebo,
Prednisolone 20mg combined with clofutriben 6mg demonstrated similar efficacy as determined by symptoms, physical function, and systemic inflammation, tikkhuorxk (znffcuqacp ) View more | Positive | 15 Jun 2024 | ||